Voyager is paying travel partner Transition Bio a single-digit million-dollar upfront payment, with additional payments up to ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

Busy Iambic Therapeutics has picked up more than $100 million in new funding as it looks to advance its portfolio of ...

In a licensing deal unveiled Monday, Lyell Immunopharma is kicking in $40 million in cash and almost 2 million of its shares ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

Molecular diagnostics firm BillionToOne raised $314 million in the DNA test maker’s upsized initial public offering but saw ...

Guardant Health is touting the results of a new study showing its Reveal blood test can detect whether chemotherapy is ...

The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study | The FDA has put a clinical hold on a Tenaya ...

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current ...

As the clinical research industry faces mounting pressures from funding constraints, evolving payer expectations and ...